Acrigen Biosciences is dedicated to making gene editing safe.
Acrigen Biosciences has raised $1.0M in total funding. The most recent round was Grant. The last funding was announced in February 2022.
Acrigen Biosciences's investors include National Science Foundation, Alexandria Venture Investments, Red Tree Venture Capital, Berkeley Catalyst Fund (BCF), Dolby Family Ventures.
Acrigen Biosciences is headquartered in Berkeley, United States.
Acrigen Biosciences is dedicated to making gene editing safe.
Acrigen Biosciences is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Acrigen Biosciences — Funding & Investors." VCBacked, February 24, 2022, https://www.vcbacked.co/company/acrigen-biosciences. Accessed November 13, 2026.
VCBacked. (2022). Acrigen Biosciences — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/acrigen-biosciences
{{cite web |title=Acrigen Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/acrigen-biosciences |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Acrigen Biosciences? Request a listing update